12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

OMS824 regulatory update

Omeros said FDA granted Orphan Drug designation to OMS824 to treat Huntington's disease (HD). Later...

Read the full 55 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >